Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30

$1.66−0.03 (-1.78%)

Close on Nov 12, 2026Market cap $590.23MP/E –Yield –

Evotec operating margin

Operating margin is operating income as a percentage of revenue.

For fiscal 2025 it was -7.1%, against -17.9% the year before. The highest annual figure on record is 14.0% in fiscal 2019.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-7.1%	+10.8
FY2024	Dec 31, 2024	-17.9%	−11.8
FY2023	Dec 31, 2023	-6.1%	−8.9
FY2022	Dec 31, 2022	2.8%	−3.9
FY2021	Dec 31, 2021	6.6%	−3.1
FY2020	Dec 31, 2020	9.7%	−4.4
FY2019	Dec 31, 2019	14.0%	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVO.

Revenue growth-1.1% · median 15.8%

Operating margin-7.1% · median -64.0%

Advertisement
300 × 250

See a number that looks wrong?